

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	21,655	97.7%	15,729	97.9%	3,285	96.4%	2,076	98.4%	153	97.5%	4,791	98.1%
Epidermoid carcinoma ^d (8050-8131)	14,299	64.5%	10,041	62.5%	2,507	73.5%	1,364	64.7%	111	70.7%	3,220	65.9%
Squamous cell carcinoma (8070)	10,401	46.9%	7,260	45.2%	1,863	54.6%	990	46.9%	89	56.7%	2,230	45.7%
Squamous cell, keratinizing (8071)	1,393	6.3%	965	6.0%	279	8.2%	120	5.7%	-	-	340	7.0%
Squamous cell, non-keratinizing (8072)	1,783	8.0%	1,318	8.2%	247	7.2%	176	8.3%	-	-	479	9.8%
Squamous cell, Microinvasive (8076)	359	1.6%	255	1.6%	53	1.6%	32	1.5%	-	-	81	1.7%
Other (8050-8069, 8073-8075,8077-8131)	363	1.6%	243	1.5%	65	1.9%	46	2.2%	-	-	90	1.8%
Adenocarcinoma ^e	6,402	28.9%	5,045	31.4%	592	17.4%	610	28.9%	38	24.2%	1,384	28.3%
Adenocarcinoma, NOS (8140)	3,250	14.7%	2,574	16.0%	286	8.4%	306	14.5%	17	10.8%	690	14.1%
Adenosquamous (8560,8570)	707	3.2%	513	3.2%	94	2.8%	90	4.3%	-	-	179	3.7%
Other adenocarcinomas ^f	2,445	11.0%	1,958	12.2%	212	6.2%	214	10.1%	-	-	515	10.5%
Other specific carcinomas ^g	431	1.9%	288	1.8%	87	2.6%	48	2.3%	-	-	79	1.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	523	2.4%	355	2.2%	99	2.9%	54	2.6%	-	-	108	2.2%
Sarcoma ^h	103	0.5%	64	0.4%	30	0.9%	-	-	-	-	20	0.4%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	256	1.2%	165	1.0%	58	1.7%	22	1.0%	-	-	38	0.8%
Unspecified (8000-8005)	153	0.7%	105	0.7%	36	1.1%	-	-	-	-	35	0.7%
Total	22,167	100.0%	16,063	100.0%	3,409	100.0%	2,109	100.0%	157	100.0%	4,884	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

- ^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.
^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.
^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.
^f Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.
^g Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.
^h Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.
- Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.
- Statistic not shown due to fewer than 16 cases during the time period.